Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients

Annals of Surgical Oncology

Volumn 20, Issue 8, 2013, Pages 2582-2589

  Shin, Hee Chul ^a   Han, Wonshik ^b   Moon, Hyeong Gon ^b   Im, Seock Ah ^b   Moon, Woo Kyung ^b   Park, In Ae ^b   Park, Sung Jun ^a   Noh, Dong Young ^b  

^a Chung Ang University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SAFETY; PREDICTOR VARIABLE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TAXOIDS;

EID: 84880262099     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2909-6     Document Type: Article

References (22)

1. Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434-42.
2. Belanger J, Soucy G, Sideris L, Leblanc G, Drolet P, Mitchell A, et al. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg. 2008;206:704-8.
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
4. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-237.
5. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-74.
6. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(2):S69-74.
7. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-16.
8. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Ann Oncol. 1999;10:47-52.
9. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001;182:601-8.
10. Enomoto K, Ikeda T, Matsui A, Kitajima M, Koh J, Masamura S, et al. Neoadjuvant therapy in stage II with T ≥ 4CM and stage III breast cancer. Eur J Cancer. 1998;34:S33.
11. Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001;19:3828-35.
12. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236:295-302; discussion 302-3.
13. Ostapenko V, Pipiriene T, Valuckas K. Primary chemotherapy in conservative treatment of stage II breast cancer patients. Eur J Cancer. 1998;34:S34.
14. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, et al. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000;88:1417-24.
15. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222:612-8.
16. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85.
17. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179-84.
18. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244:464-70.
19. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012;135:619-27.
20. Botteri E, Rotmensz N, Sangalli C, Toesca A, Peradze N, De Oliveira Filho HR, et al. Unavoidable mastectomy for ipsilateral breast tumour recurrence after conservative surgery: patient outcome. Ann Oncol. 2009;20:1008-12.
21. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303-12.
22. Fitzal F, Riedl O, Mittlbock M, Dubsky P, Bartsch R, Steger G, et al. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast Cancer Res Treat. 2011;127:121-8.